New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

June 14, 2022

The response rate to DBV Technologies SA’s drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

DBV Technologies SA’s (DBVT:NASDAQ) Viaskin patch for peanut allergy in one to three-year-olds was shown to be effective and safe in a Phase 3 clinical trial, reported H.C. Wainwright & Co. analyst Andrew Fein in a June 8 research note. This is significant because no approved therapy exists for youngsters with this condition.

Generally, the EPITOPE trial demonstrated that 250 micrograms of Viaskin epicutaneous immunotherapy, after one year, achieved the primary endpoint of difference between the percentage of treatment responders in the active versus placebo cohorts.

Specifically, after one year, 67% of treated patients versus 33.5% of placebo patients met responder criteria, Fein relayed. This translates to a statistically significant response rate of 33.4% (p<0.001).

“We highlight that the lower bound of the 95% confidence interval was 22.4%, comfortably exceeding the prespecified 15% threshold,” the analyst added.

The EPITOPE trial also showed the safety profile of Viaskin 250 micrograms in one to three-year-olds is consistent with that in children aged four years and older. Mild to moderate skin reactions at the patch site were the most common adverse events.


Free Reports:

Get Our Free Metatrader 4 Indicators – Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter





Get our Weekly Commitment of Traders Reports - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.





Fein pointed out that the safety profile of Viaskin is better than that of Palforzia, an approved oral peanut allergy drug for four to 17-year-olds. In EPITOPE, of the patients who received Viaskin, 1.6% had an anaphylactic reaction, from or not from the drug, which did not require epinephrine. This compares to 9.4% of patients with oral Palforzia, which occurred in trials not related to Viaskin.

Based on these positive EPITOPE data, DBV Technologies will continue advancing Viaskin toward approval in this early age group.

Fein highlighted that the French biopharma has a second shot on goal with Viaskin, and that is with a modified Viaskin patch for children ages four to 11 years. DBV Technologies has a Type C meeting with the U.S. Food and Drug Administration scheduled this quarter to discuss and finalize the protocol of the next planned trial in this regard, Phase 3 VITESSE.

“The main difference between the patches is the size and shape of the overlay itself, with the same occlusion chamber design, intended to satisfy optimized delivery,” Fein explained.

H.C. Wainwright has a Buy rating and a $10 per share price target on DBV Technologies, the stock of which is currently trading around $2.85 per share.

Disclosures

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional, and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice, and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for H.C. Wainwright & Co., DBV Technologies S.A., June 8, 2022

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position).

As of May 31, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in DBV Technologies S.A. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.

No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.